Algert Global LLC Purchases 40,489 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Algert Global LLC increased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 165.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 64,961 shares of the company's stock after buying an additional 40,489 shares during the quarter. Algert Global LLC owned about 0.12% of Janux Therapeutics worth $3,478,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Russell Investments Group Ltd. increased its holdings in shares of Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after acquiring an additional 442 shares during the last quarter. Avanza Fonder AB acquired a new position in shares of Janux Therapeutics in the 4th quarter valued at $139,000. Meeder Asset Management Inc. purchased a new position in shares of Janux Therapeutics in the 4th quarter valued at $159,000. Tower Research Capital LLC TRC raised its stake in Janux Therapeutics by 878.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock worth $205,000 after acquiring an additional 3,436 shares in the last quarter. Finally, Chicago Capital LLC acquired a new stake in shares of Janux Therapeutics in the fourth quarter valued at approximately $230,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Down 0.2%

JANX stock traded down $0.05 during midday trading on Monday, hitting $25.52. 422,332 shares of the company traded hands, compared to its average volume of 984,871. Janux Therapeutics, Inc. has a twelve month low of $22.52 and a twelve month high of $71.71. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -21.88 and a beta of 3.24. The business has a 50 day simple moving average of $29.27 and a 200-day simple moving average of $41.59.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.04. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Analyst Upgrades and Downgrades

JANX has been the subject of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Wedbush restated an "outperform" rating and set a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, Scotiabank lowered their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Janux Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $95.25.

Insider Buying and Selling

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the completion of the sale, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $2,640,768.85. The trade was a 3.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. acquired 110,206 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the acquisition, the director now directly owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. This trade represents a 1.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 10,001 shares of company stock worth $313,964 in the last quarter. 8.10% of the stock is owned by corporate insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.